Abstract 8546

Article

Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL)

Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL)

M. Demierre, S. Whittaker, Y. Kim, et al

Methods: Data from two clinical trials were pooled for more accurate estimates of endpoints and subpopulation investigation. All patients had confirmed cutaneous T-cell lymphoma (CTCL) and all 96 in one study (GPI-04-0001) had received ≥ 1 prior systemic therapy. Patients received romidepsin 14 mg/m2 as a 4-hr infusion on days 1, 8, and 15 every 28 days until disease progression. The primary efficacy endpoint for both studies was overall response rate (ORR) using a composite endpoint that included skin assessment, lymph node and visceral involvement and abnormal circulating T cells/Szary cells.

Results: Among 167 patients (mean age 57) receiving romidepsin (as-treated), 135 patients (81%) received ≥ 2 cycles of treatment and were therefore evaluable for efficacy. Stage ≥ IIB disease was reported in 103 patients (76%). The median number of prior systemic therapies was 2 (range 1–8). The ORR was 41% among evaluable patients and 35% among as-treated patients (see Table):

 

Evaluable pts* (n = 135)

As-treated pts (n = 167)

ORR, n (%; 95% CI)

55 (41%; 32.4%–49.5%)

58 (35%; 28.1%–43.2%)

CR, n (%)

10 (7%)

10 (6%)

PR, n (%)

45 (33%)

48 (29%)

Median duration of response

14.9 mo

13.8 mo

Median time to disease progression

8.3 mo

6.6 mo

*Received ≥ 2 cycles
CI = confidence interval; CR = complete response; ORR = overall response rate; PR = partial response.

Responses were noted in 42% of patients with stage ≥ IIB disease, in 11 (58%) of 19 patients with Szary syndrome (erythroderma + Szary cells, >1,000/mL or >20% ), in 20 (38%) of 52 patients who received prior bexarotene (Targretin) and 8 (40%) of 20 patients who had received denileukin diftitox (Ontak). The most common drug-related adverse events included nausea (67%), fatigue (49%), anorexia (37%), ECG T-wave changes (29%), anemia (26%), dysgeusia (23%), neutropenia (22%), and leukopenia (20%). Related serious adverse events reported in 2% of patients included supraventicular arrhythmia, ventricular arrhythmia, infection, neutropenia, white blood cell decreases, hyperuricemia, and hypotension. Three deaths were reported as possibly drug-related.

Conclusions: Based on the ORR, CR, durability of response, improvement in all disease compartments, and responses at all stages and in all subpopulations analyzed, romidepsin is a valuable new therapy for patients with CTCL.

Related Videos
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
2 KOLs are featured in this series
2 KOLs are featured in this series
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
Eric Singhi, MD, and the Oncology Brothers presenting slides
Eric Singhi, MD, and the Oncology Brothers presenting slides
Eric Singhi, MD, and the Oncology Brothers presenting slides
Eric Singhi, MD, and the Oncology Brothers presenting slides
Related Content